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From Prison to the Community: Opportunities for Pharmacists to
Support Inmate Medication Adherence
Abstract

The United States correctional system is a vital treatment source for chronic illnesses. Whether treating a
chronic mental or physical illness, correctional healthcare requires effective resource utilization. Limited
research exists on pharmacists' ability to directly address inmate medication adherence. Thus, this study
explores inmate perception of medication adherence and management as part of their treatment plan. Semistructured interviews were conducted with inmates throughout Connecticut. Diseases of interest were
divided into a physical illness group (hypertension, diabetes mellitus, HIV/AIDS) and a mental illness group
(depression, bipolar disorder, schizophrenia, substance abuse). A content analysis was conducted on four
questions: 1) Do you take your medications as prescribed, and why? 2) How do you feel about taking
medication for your illness? 3) Are you experiencing any problems or side effects due to your medications and
how do you handle this? and 4) Have there been any changes to your medications and how was this process
handled?
Interviews were conducted between January and December 2015 with 23 male inmates (n= 7 in prison; n=16
in halfway houses). A total of 6 inmates reported non-adherence, 17 reported adherence, 7 had a physical
illness, and 16 had a mental illness. A total of 16 themes were identified through the four questions.
Overall, the pharmacist's medication knowledge and availability allow for medication management and
support of inmate medication adherence. Inpatient, pharmacists are suited to perform comprehensive
medication therapy management for the psychiatric population and other chronic illnesses. Outpatient, the
community pharmacist is poised to supply medication information and guidance to transitioning inmates.
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Introduction
The purpose of this study is to investigate the way pharmacists can serve
incarcerated and newly released prison populations by addressing medication
adherence and managing medication therapy. Interviews were conducted to gauge
inmates’ opinions of their medication regimen, experience with the health care
system, and ultimately identify factors most important for effective medication
therapy management. Feedback gained from these interviews will help define
how the pharmacist, whose clinical responsibilities have expanded, can better
support medication adherence among incarcerated individuals. The data for this
paper comes from a cross-sectional parent study entitled “Interviews with Inmates
on Self Care Needs”, also known as “Inmate Self Care”. This study examines a
subset of interview data from the parent study answering the question: How do
correctional patients perceive medication adherence and medication management
as a part of their treatment plan?

Background
Health care in the United States (US) is moving towards a value-based care model
where health resources are being strategically used to achieve the “Triple Aim” of
lower health care costs, improving population health, and improved patient
experience1. Major goals of this movement include care coordination and
addressing both the tangible and intangible aspects of health care1. Highly
important to this movement is patient medication adherence, defined here as the
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extent that patients take medications as prescribed by their health care providers2.
When put into practice, medication adherence has the potential to drive significant
savings for health systems by controlling chronic conditions, preventing hospital
readmissions, and decreasing morbidity3. The system-wide cost of drug-related
problems such as non-adherence was shown in a 2008 study conducted by the
New England Healthcare Institute to be over $290 billion- a total that has likely
increased due to inflation4. Recent data shows about 49% of Americans take at
least one medication and between 35-50% are non-adherent5. If prescribed
medications are neglected, patients generally do not achieve targeted health
outcomes and may see a worsening of their condition. As well, non-adherence can
put patients at higher risk for mortality and the associated costs of intensive
inpatient services when admitted to the hospital, with over 10% of
hospitalizations attributed to lack of medication adherence3,6. With that,
addressing medication adherence can bring about a multitude of benefits and fits
into health care’s new culture of improved patient outcomes through increased
care quality.
The US prison population represents a diverse body of individuals with a wide
array of chronic illnesses. As of 2014, over 2.2 million individuals are currently
sentenced in a Federal prison, State prison, or local jail at a rate of 900
incarcerations per 100,000 US residents- one of the highest rates in the world7.
Among the correctional population, there is a high incidence of mental health
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illness, with a Department of Justice study estimating that 45% of Federal, 56% of
state, and 64% of local jail inmates suffered from at least one mental illness8.
These conditions include bipolar disorder, schizophrenia, depression, and others
that often go undiagnosed during the inmates’ life. The same report showed that
74% of state and 76% of federal prisoners with mental illness, respectively, were
also likely to exhibit substance abuse8. Aside from those with a mental illness, the
incarcerated population exhibits diseases comparable to the free world such as
hypertension, diabetes, and HIV9. A recent study estimated that 40% of inmates
have a chronic illness of a physical nature, irrespective of mental illness10. In
practice, correctional health care occurs in a highly coordinated and regimented
environment when compared to the free world. Although inmates are regulated
and under intense scrutiny, non-adherence continues to exist because, like in the
free world, inmates can choose to neglect their treatment or refuse prescribed
medication regimens.
Progressing through the correctional system, inmates in need of treatment,
often referred to as inmate-patients, face a diverse set of health care-related
obstacles. Periods of transition are especially challenging for maintaining
adherence as inmate-patients face relocation, insurance change, and complete
reestablishment of their medical care team. With over 600,000 prisoners released
to the community in the US on an annual basis, the challenge is widespread and
readily apparent11. On release, inmate-patients must relearn the community-based
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system they once participated in, while adapting to changes that have been made
since the Affordable Care Act (ACA) in 2010. When transitioning at the end of a
sentence, inmates will be directly released to the community, while others,
released under transitional supervision, will exit prison in a stepwise-approach
and spend time in a halfway house12. On departure from correctional health care,
to either the community or a halfway house, an inmate must assume full
responsibility for their health care and will often depart with a short supply of
medication13, or voucher. In either case, those on chronic medication therapy will
eventually need to refill their medications and it is then that the inmate will
encounter an important community health care provider; the pharmacist.
For inmates and the community as a whole, the pharmacist presents as a
viable resource for promoting medication adherence and managing medication
therapy. When considering access to health care, the pharmacist is viewed as the
most accessible health care professional and consistently ranks in the top most
trustworthy professionals14,15. With over 110,000 total pharmacists employed by
chain retailers and independent pharmacies in the US, the public can’t go far
without encountering a pharmacist16. The services of the pharmacist are unique in
that there are few other instances in the US health care system where an
appointment is not required to receive free professional input. A pharmacist’s
education includes extensive training on side effect monitoring, preventing drug
interactions, and optimizing both the safety and efficacy of medication regimens;

5

making them well-equipped to resolve adherence discrepancies17. In addition to
pharmacotherapy management, pharmacists receive communication training to
better elicit information from patients and motivate change in those that want to
alter their habits in a positive way17. Recognition of pharmacists’ capabilities is
becoming apparent as professional organizations increasingly call for their
involvement in addressing unmet public health needs, drawing the profession
further into patient care.
At the national level, professional organizations such as APhA are lobbying
for attainment of pharmacist provider status in rural and underserved areas18.
Pharmacists already receive compensation from the federal government through
Medicare Part D for Medication Therapy Management (MTM), a comprehensive
medication review aimed at increasing safety and efficacy of medication
regimens, but federal provider status recognition would allow for expanded
clinical scope19. The components of MTM have been standardized through input
from several professional organizations and have been formally compiled as a
resource called the “Patient Care Process”20. Here the pharmacist conducts MTM
with the patient’s preferences and outcomes at the center of their service. Aside
from the federal movement, Collaborative Drug Therapy Agreements (CDTA) at
the state level give pharmacists prescriptive responsibility for specific diseasestates or specific populations of patients21. Here, pharmacists play a greater role in
therapy management as an extension of the traditional physician-patient
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relationship. Recently, the American Society of Health-System Pharmacists
(ASHP) released the first guidelines on pharmacists’ role in correctional health
facilities, advocating that facilities obtain the services of pharmacists to ensure
safe and effective care; a sign of pharmacists’ evolving role and ability to impact
care in diverse settings22.
Availability, knowledge, and expanding services make the pharmacist
ideal for medication therapy management and promotion of medication adherence
for all participants in the health care system. Inmate-patients, who represent a
vulnerable population with limited resources and a high comorbidity burden, may
benefit from pharmacists’ services and ultimately experience improved health
outcomes. Thus, this study seeks to explore factors affecting inmate medication
adherence that may be influenced by pharmacist intervention. Justification for the
present study stems from the structural care processes and patient needs that are
inherent to the correctional health setting. By conducting exploratory interviews
with inmate-patients, opportunities for pharmacist intervention will be defined
and additional hypotheses concerning medication adherence will be generated.
These opportunities will ideally target the root cause of non-adherence and guide
future work to support adherence to obtain positive health outcomes. With the
efforts brought on by the ACA to facilitate inmate participation in healthcare and
support from many professional organizations, the progressing role of the
pharmacist can be further refined to address inmate-patients' health needs.
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Methods
Parent Study
The data for this analysis comes from an ongoing parent study called the “Inmate
Self Care” study that began in 2014. The purpose of “Inmate Self Care” is to
explore the factors affecting inmate-patients’ ability to perform self-care in a
correctional setting. The study’s ultimate goal is to develop a solution, in the form
of a patient-centered tool or policy recommendation, to improve inmate-patients’
self-care habits and allow them to receive the greatest benefits from care. “Inmate
Self Care” also served as an internship opportunity for pharmacy students to
participate in data collection and data analysis for an interprofessional research
project.
Contractual authorization for the study was obtained from the Connecticut
Department of Corrections (CDOC) and a Certificate of Confidentiality (# MH14-63A) was obtained from the National Institutes of Health (NIH). Study
participants were recruited from two Connecticut Correctional Institutes and eight
work-release or inpatient halfway houses.
Planned enrollment for the parent study was 140 participants with the
following characteristics: male, female, adherent, non-adherent, diabetes mellitus,
HIV/AIDS, hypertension, depression, bipolar disorder, schizophrenia, and
substance abuse. The planned enrollment is further outlined in Appendix- Table 1.
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Semi-structured interviews were utilized to explore inmate- patients'
perspectives on adherence to medication and medication management in a
correctional setting. Thirty questions were developed as an exploratory core for
the parent study based on previously identified psychosocial and pharmacologic
factors affecting treatment adherence23–25. Efforts were made to probe interview
participants in order to provide further insight into interview questions.
Demographic information was collected including date of birth, gender, ethnicity,
education level, work history, family support, and current chronic medical
conditions. Completion of all interview questions was expected to take 30-45
minutes based on applicability to each participant and depth of response.
Adherence status would be assigned after review of the participant’s
medication administration record (MAR) for the previous three months. If the
patient took 80% or more of their prescribed doses, they were considered
adherent; non-adherent if they did not meet this threshold26,27. If the MAR could
not be obtained, adherence would be assigned based on participant self-reporting.

Sub - study Design
Following the same projected enrollment as the parent study, this study sought to
answer the following question: How do correctional patients perceive medication
adherence and medication management as a part of their treatment plan?
Assessing this question has important implications for pharmacy practice because
it offers insight into inmate-patients’ day-to-day health care experience

9

throughout the correctional process. Such insight will help define opportunities
for pharmacist intervention, allowing for optimal use of resources and attainment
of beneficial health outcomes.
To address this, four questions were selected for primary analysis from the 30
parent study questions:
Question 1 (Q1)- Do you take your medications as prescribed, and why?
Question 2 (Q2)- How do you feel about taking medication for your illness?
Question 3 (Q3)- Are you experiencing any problems or side effects due to
your medications and how do you handle this?
Question 4 (Q4)- Have there been any changes to your medications and how
was this process handled?
These questions were selected specifically for their focus on medication
adherence and management. The former is addressed by both Q1 and Q2, which
serve to elicit more information about the inmate’s overall adherence and
perception of medication. The latter, addressed by Q3 and Q4, targets inmates’
experience with medication changes and their interactions with providers through
the management process.

Sample
For inclusion in the study, participants were required to be over the age of 18,
currently prescribed a treatment for a chronic illness, English speaking, and have
an incarceration history of at least 6 months. Chronic illnesses of interest
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included: depression, bipolar disorder, schizophrenia, substance abuse,
hypertension, diabetes mellitus, and HIV/AIDS. The participant’s primary
diagnosis with active treatment determined categorization into either a physical
illness group consisting of hypertension, diabetes mellitus, and HIV/AIDs; or a
mental illness group consisting of depression, bipolar disorder, schizophrenia, and
substance abuse. These diseases were chosen because they are frequently
occurring in the general population, can be maintained with appropriate
medication regimens, and generate significant costs when the diseases are
uncontrolled. Adherence status was determined based on inmates’ self-reported
medication adherence for the previous 3 months.

Study Recruitment
Participants for the sub - study were recruited from one Connecticut Correctional
Institute and four work-release or inpatient halfway houses. Recruitment
procedures included use of posted fliers advertising the study which were hung in
each facility through coordination with CDOC personnel. Each flier noted criteria
for study enrollment with instructions to place a note in the sick call box if
interested. Recruitment periods covered two weeks, at the end of which a date
was coordinated with the CDOC staff to interview all interested inmates. The
purpose, procedures, minimal risk, and potential lack of direct benefits of
participating in the study were discussed on first meeting participants. Informed
consent was then obtained, with participants acknowledging that they had the
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right to refuse audio recording, could refuse disclosing their medication
administration record, could abstain from answering any question, and could
leave the interview at any time with the interview materials being subsequently
destroyed. Signed informed consent forms were retained and stored separately
from subsequent interview documentation to maintain de-identification.

Interview Procedures
On the determined interview date, researchers met with inmates in the general
visitation room or private consultation rooms. At the start of the interview,
inmates were provided full details of the study, informed of the NIH Certificate of
Confidentiality, and written informed consent was obtained. Interviews followed
a semi-structured format, were audio recorded, and handwritten notes were taken.
In addition to the interview questions, demographic information was obtained
from each participant including their medical conditions and current medication
regimen. Each interview was de-identified through the replacement of the
inmate’s name with a number starting with 01. Audio recordings were later stored
on an encrypted computer to maintain security. Individual interview notes were
stored in a double-lock system, e.g. in a locked cabinet within a locked room at
the University of Connecticut.

Analysis
Each interview was transcribed by a member of the research team and was
subsequently reviewed by a different team member. During transcription, a
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concerted effort was made to highlight the inmate’s phrasing of certain answers,
points of emphasis, and any other verbal cues that could elude their emotional
stance on the topic. To ensure accuracy, 20% of interviews were validated
through performing a second transcription by another team member and were
cross-checked with all supporting notes. The interview transcripts, procedures,
and analysis were reviewed by a veteran nursing professor to further ensure
accuracy.
Content analysis began with a focused review of all transcripts by the research
team with all analysis performed using NVivo 11 Pro (version 11, QSR
International). The analysis was guided by previously identified psychosocial and
pharmacologic factors affecting medication adherence23–25. After an initial review
of all interview transcripts, responses to each question were interpreted and their
underlying context served as themes. These themes were coded as nodes in
NVivo and a node hierarchy was continually refined throughout the analysis.
After coding all transcripts, each node was reviewed to determine if saturation
was reached. After saturation was reached, themes were finalized for each
question, and representative quotes were identified.

Results
Sub - study Sample
All sub - study interviews were conducted between January and December 2015,
each averaging 30 minutes in length. The sub - study sample included 23 male
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inmates located in one prison and four halfway-houses throughout Connecticut
(Appendix- Table 2).

Content Analysis
In total, 6 inmates were non-adherent, 17 were adherent, 7 had a physical illness,
and 16 had a mental illness. For the physical illness group, 1 was non-adherent
and 6 were adherent. Among the mental illness group, 5 were non-adherent and
11 were adherent. All inmate-patients that consented to participating in the study
fully-completed their interviews and there were no study dropouts. The 4 selected
questions, out of 30 original study question, were coded with NVivo 11 Pro and
their respective themes are presented on a question-by-question basis. Quotes are
provided from the respective study participants. Overall 16 different themes were
identified and reached saturation (Appendix- Figure 1). These themes could then
be further classified as promoting adherence, non-adherence, or impacting
medication management (Appendix- Table 3).
Q1. Do you take your medication as prescribed, and why?
In gauging patient’s perceptions of medications, it was first necessary to
determine whether or not patients were taking their medications and why. Themes
identified for Q1 included: Momentary Disruptions, Timeliness, Lack of Need,
Personal Beliefs, and Patient Education.
Momentary Disruptions
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Most of the instances of non-adherence could be considered temporary in nature
and resulted from momentary disruptions to an inmate's normal habits. As
expected, it was rare that inmates reported simply forgetting as a reason for nonadherence. Several of the reasons for non-adherence related to procedures
associated with medication administration. One inmate described not taking his
medications because the nurse was not using gloves, making the medications
unsanitary:
“I don’t like the way some nurses here give out medication. Like the other
day, I was going to refuse my meds…The nurse started dumping my
pills…A couple of the pills fell out onto the counter and she did not have
any gloves and she felt it was alright to scoop up the pills with her bare
hands back into the cup and hand me the cup. This got me mad because
you are not going to go to a restaurant and let a waitress or waiter grab
your food or play with your food with their bare hands. This is something
that is going into my mouth and my body.” (02)
In one case the prison’s evening medication call conflicted with the television
show American Idol, and thus his medications went untaken:
“P:...I missed it because they called us out at around 8:30 to get our meds
and I was watching American Idol and did not want to miss it.
I: Was that for all the medications?
P: Yeah for all of them. I am pretty sure.” (02)
Timeliness
The amount of time required to obtain their medication was also a factor driving
non-adherence. In dealing with the medication line, it was stated that the nurses
take too long, causing the inmate to become frustrated with waiting and then exit
the medication line before receiving their dose:
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“Um, the nurse that we have is just too slow. And I’m not part of standing
in line and waiting forever. I said you know what, I told the CO, mark me
as a refusal. I refuse everything.” (01)
In acute instances where over-the-counter (OTC) medications were needed, such
as joint pain or relief from a common cold, inmates could obtain necessary
medication from the commissary. Here, OTC products could be purchased
through an inmate’s bank account, providing expedited relief compared to the
health system at a comparable price:
“Patient (P): …they (the nurse) would find out our symptoms and write
them down in our file to be referred to a doctor.
Interviewer (I): Would they ever turn you away and say go to
commissary?
P: Umm they always just tell us to go if you got money on the books
‘cause it costs you 3 dollars anyway. To see the doctor is another 2-3
weeks.
I: Did you find yourself buying a lot of OTC products off the commissary?
P: I did everything. Antihistamines, Tylenol.” (19)
Lack of Need
Inmates often expressed periods where they were sufficiently maintained on
therapy and had a perceived lack of need for their medications. An instance of this
occurred during a “reality check”, where the patient wanted to check the status of
their condition without medication:
“I just wanted to feel again, I just wanted to see how good I was really
doing. And it was just like a reality check.” (09)
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Here, another inmate described “highs” that caused him to see no need for
medications. After stockpiling skipped doses, their mental condition would
decline and they would eventually overdose on the accumulated medication:
“Yeah it’s just I’m just in one of my moods, you know, I’m on one of my
highs you know where I’ve been doing really good for a while and I’m
like “you know what today I don’t need it, tomorrow I’ll take it. I’ll do the
cheat method where I just put it underneath my cheek or underneath
my…I’ll stack them in my cell like I took them for a couple of days and
then because I haven’t been on them for a while my depression comes
back and now I get depressed, now I have thoughts of hurting myself, so I
immediately get attention. I’ll be like “Oh yeah you want to do that? Well
watch this, see these pills?” And the guy will call the court and I’m getting
all the attention. Then I’m on the meds, I’m doing what I’m supposed to
be doing. And then I’m like I’m doing so well I don’t need the meds
anymore, and then I slide back down and crash for a while and then I get
back on them. (01)
Personal Beliefs
At times, inmates presented with a strong belief, most often unfounded, that
influenced their adherence. Here a patient reported not taking his medication over
fear of drug tests resulting in a false positive:
“I’m trying not to take a lot of it because I was told it could make a false
positive…that’s why I stopped taking everything cuz I want to make sure
that my tests are clean.” (11)
One inmate with a mental illness mentioned a general embarrassment from taking
psychiatric medications, but noted the benefits gained from treatment. In this way,
the negative impact of public opinion was present and acknowledged, but the
inmate continued to actively participate in treatment:
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“I am more embarrassed by it. Ashamed I guess you could say. I am not a
control freak but I like to be in control of myself, which I am sure
everyone does. We are adults not children. I do not like the fact I have to
use chemicals to stay in control of myself, but I guess that is something
personal I have to get over.” (02)
Patient Education
The beneficial effects of patient education were seen through adherence, as one
inmate described how his doctor helped establish a regimen that best suited his
needs:
“…if it’s one thing I will say, and I’ll only give credit to doctor I had
when I first came in, she was very patient with me, and understanding that
I didn't want to be all doped up on meds…but the lithium itself, that’s
really done wonders. It really just stopped the suicidal thoughts from
happening, like just cold turkey…so I really give the credit to the
medication and taking them as prescribed.” (03)
Q2. How do you feel about taking medication for your illness?
After determining adherence, the inmate’s perception of medication’s role in
therapy was subsequently analyzed. Whether medications were valued or not,
along with the perceived benefits or risks, and the reasons supporting their
answers were elicited through this question. Themes identified for Q2 included:
Tangible Benefits, Potential Risks, Acute Relief, Counseling, Loss of Faith.
Tangible Benefits
For those finding value in medications for their condition, the most readily
apparent theme identified was tangible benefits. Whether a mental or physical
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illness, those supporting medications gave clear examples of the benefits they
received:
“Effexor is a miracle drug. I’m happier now… even in the world I had
problems, suicide and stuff like that, and you know, suicidal thinking, and
then umm when they put me on Effexor, it just you know kind of evened
everything else.” (08)
“Well listen, when I’m over 20 years for HIV and I’m never get better but
never got full blown AIDS, the medication is doing something.” (12)
Potential Risks
Many others were motivated by the potential risks of an uncontrolled illness such
as diabetes, an underlying heart condition, or feeling the negative physical effects
in the absence of medication:
“Since I have been in I take everything. I am not risking going blind just
because I do not want to take some pill.” (21)
“I have an issue in that area so imma be on my meds, you know because
high blood pressure do that to your ticker. And I always had a little heart
problem, since ’91 they told me I had a little black spot on the back of my
heart.” (22)
“I'm taking the water pills, I know I can't breathe- you know? And I know
that pill is doing me good- you know? If I have any problems I make sure
I take that water pill- you know?” (23)
Acute Relief
In some cases, the acute benefits mattered most to the patient such as during an
anxiety attack:
“…it's like sometimes like every time it pop I need to take ‘em. I don’t
want to have that, because I see people dying from anxiety, you know?
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And I don’t want that to happen. Like, last week it was bad. I was like, I
can't breathe I can't breathe, can you take me to the Doc?” (15)
Counseling
Another common theme was the benefits of group therapy and the different forms
of expression it provided patients:
“And the treatment helps give me outlets, different outlets to take- you
know? My major outlet was violence, and drinking and drugging. And the
therapy and the treatment helps me, like there is different avenues- you
know? Like I said I never wrote poetry in my life, I’m like that’s for saps.
And I’m like one of the toughest poets now. I sit there and I’m like ughhh
and then by the time I finish I’m like oh my god, I wrote over two pages!”
(17)
One inmate acknowledged both the benefits of new medications and counseling
programs on release from solitary confinement. Here he stated that a change in
environment and access to groups led to all-encompassing benefits:
“Um it’s hard for me to tell because I was in solitary confinement for 16
months in the super max, and again how I got there was because I was on
medications that weren’t working …I’m not sure if it’s because I have a
lot more freedom because I’m not locked in a cell 23 hours a day with
minimal human contact. So, there’s a lot more freedom for me to do
programs like NA and AA, there was also a dual recovery program for
people who have mental health problems and addiction. Um, really just
services, and then we have creative writing and theatre classes. Plus, I’m
able to have rec twice a day. Soooo- I don’t know if it’s that or the
medication I’m taking or a combination of both.” (07)

Lack of Faith
Instances where inmates saw little value in their medications were rare, occurring
in only 4 interviews. In a broader sense, inmates’ non-adherence derived from a
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greater loss of faith in the health care system and the treatment they received. One
inmate placed no value in his medication regimen because of being through the
process so many times and feeling like a “guinea pig”:
“Yeah um I’m kinda skeptical about medications. Because I’ve been doing
this for so long I kind of feel almost like a guinea pig. Like there’s no fix it
pill. Ya know what I mean? Um, I’ve like I said taken so many
medications over the years.” (07)
Disinterest in medications arose from lapsing refills, where an inmate located in
the halfway house ran out of their current supply without a follow-up prescription:
“P: …just recently I ran out of high blood pressure pills. When does the
doctor anywhere, unless he knows your blood pressure is safe, take you
off pills and say there is no refills? I’ve been taking these things for like
10-15 years.
I: Oh, so you didn’t have any refills?
P: There's just no refills. What are you out of your friggin mind? Now I'm
running around here with no pills and high blood pressure and sure enough
I got pissed at someone the other day and yelled at them and got written
up.” (18)
Q3. Are you experiencing any problems or side effects due to your
medications? How do you handle this?
Side effects often play a major role in medication adherence; thus, it was
necessary to explore inmates’ experience with medication side effects. In this
way, their medication management and resulting adherence could be better
understood. Themes identified for Q3 included: Cognitive Side Effects, Therapylimiting Side Effects, Physical Side Effects, and Patient Education. Side effects
reported were seen with antipsychotics or mood-stabilizing medications causing
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significant mood changes, drowsiness, weight gain, or extra-pyramidal side
effects (EPS), or reported by patients with a mental illness. This often-fostered
disinterest and non-adherence in the medication regimen.
Cognitive Side Effects
As mentioned, changes in mood often had an adverse impact on the patient and
required therapy change:
“I was on Abilify and I stopped taking that. There was a big issue here
surrounding me being taken off that medication because it made me feel
almost frantic. I do not know why or what caused it. I don’t know if it was
the pills or dosage, but it gave me this feeling that if I did not get
something done right away that something bad would happen.” (02)
Drowsiness is a common side effect for antipsychotics and can be another source
of medication discontinuation. Here the side effect was viewed in both a favorable
and unfavorable light:
“P: Sleepiness, drowsiness. Trilafon puts me asleep. Not too much, but
makes me a little drowsy. (pause). Other medications I don’t think there
are any side effects that really bother me.
I: Are you annoyed by the drowsiness?
P: Not really, I don’t have nothing else to do but sleep.” (02)
“What they want is a therapeutic level and you know usually the
therapeutic level got me where I’m drowsy...you know I feel like I’m not
myself and you know I don’t like that feeling.” (01)
Therapy-limiting Side Effects
The presence of EPS, facial twitching and other involuntary movements, is a
constant concern with antipsychotic medications and is often a treatment limiting
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factor. Here a patient exhibited signs of EPS which led to a change in their
therapy:
“I: Do you have any problems or side effects that you think you can
attribute to your medications?
P: yeah - well - tremor in hand…my lip was like moving, involuntarily too
- but umm, they switched my medication up and the pros and the cons
outweighed the pros or whatever it’s called.” (08)
Physical Side Effects
An example that appeared several times was significant weight gain from lithium.
Patients noted the benefits of lithium but stated that the additional weight was
impacting their lives. The additional weight gain presented as a common factor
for patients wanting to change their medications:
“…I’m trying to get off my lithium because it is bloating me. It’s like,
making me overweight I think. I’ve gained a lot of weight on the lithium.
More than I’ve ever had in my life…it was actually dramatic…I ended up
gaining like 40 pounds in like 4 months.” (05)
Patient Education
Inmate-patients demonstrated an understanding that doses are titrated for
optimum effects but complained of negative side effects on dose increases;
especially with psychiatric medications. These changes were mitigated by care
providers explaining what was happening and assuring the inmates that this
experience was only temporary. In this case, the nurse was supportive of the
patient going through a dose increase:
“Every time I go through the increase, for a couple days I get real bad
headaches, my hands start shaking real bad and um, I just don’t like the
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feeling. So, she kinda worked with me she said ‘okay well what we will do
is we will keep you at where you are at…if you start acting out again,
we’re just going to increase your meds and you can refuse them then we’ll
go from the next step from there but as of right now, you know, you can
stay at it’.” (01)
Q4. Have there been any changes to your medications? How was this process
handled?
Inmate-patient’s medication regimens undergo change for a variety of reasons and
the processes surrounding these changes vary. The goal with this question was to
elicit information about the management of inmates’ medication regimens to
identify practices that influenced adherence. Themes identified for Q4 included:
Patient Education, Unmatched Expectations, Limited Provider Access, and Data
Use.
Patient Education
When changes were necessary, clinicians took time to explain the therapeutic
alterations. Inmates reported that they were consistently informed why a
medication was added or discontinued, or why a dose was changed. In many cases
the education received from the care provider had a large impact on the patient’s
participation in treatment:
“I was really lucky when I first came into the county system, the doctor
I had, she was, uh very, very nice, very educated, very professional, but
more than understanding, so from the very start, she addressed my main
concern which was medication. I didn’t want to take medication, not
that I didn't believe in it, but first hand I saw what medication um, does
to some of the patients that I worked with, when they had been
medicated, and I didn't want to get diabetes, anger issues, violent
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tempers.” (03)
“Dr. G spent time with you and showed you how important it is to take
the medication, and if you don’t take it this could happen... if you don’t
take them correctly or if you don’t mix them up correctly they don’t
work. Dr. G always used to explain correctly. He cared more for us…he
explained everything correctly and prescribed me the right medicine
and so I believe that with him is the reason I’m still here because I
lasted so long and taught me more about my disease that I have. Dr. G
taught me that if I skip a day or two the virus can figure out the
medication and the medication won’t work for me so I always try to
take it but in the world it’s hard for me." (20)
Unmatched Expectations
At times medication changes were not always welcome, and opinions of alteration
to the medication regimen were different between patient and provider. One
inmate reported his provider wanted to change his medication dose, but he
resisted due to comfort at the current dose. In this case, a change to the inmatepatient’s regimen may have caused a moment of instability:
“I don't really like when people mess with my medication. Cause I’m
doing well, even though - since I am doing well they say we need to
start cutting back on your medication. I mean come on, I’m doing well,
why mess with my medication- you know?” (08)
Limited Provider Access
Access to care, limited by physical and administrative barriers, played a large role
in the degree to which medication changes could be made. One inmate, who had
just arrived in the halfway house, sought to resolve his lithium side effects but
was unsure how to do so:
“I: Have you talked to your doctor about that?
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P: No, I’ve gotta talk to them, I don’t know how. I’ve gotta figure out how
to go about doing that because you go back into the jail to do that so…”
(05)
Data Use
Medication changes were also the result of blood level monitoring, as in this case
where an inmate’s prolactin levels called for a change to their medication
regimen:
“…there was a point in time where they were trying to decrease the
medication and then I started to get agitated and my mood started to
change…they stopped giving me Risperdal cause of my prolactin
levels…and I started getting a sensitive chest…they put me on
Zyprexa instead of Risperdal.” (08)
While monitoring blood levels for certain medications can lead to appropriate
therapy selection, one inmate presented what occurs when labs such as viral load
are neglected:
“P: …he was the one that took me off my meds back in 2005…I lost my
weight, I went from 235 down to 167 pounds
I: Okay what was it he took you off, do you remember, or what it was for?
P: My HIV
I: Did he replace it with anything?
P: No
I: So how long do you think you were without treatment for your HIV?
P: At least a few months
I: And then he started back up again?
P: Yeah when he saw my numbers but I was telling him all along I had
problems, so they took my gallbladder...” (22)
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Discussion
Thematic Overview
The 23 inmates interviewed provided perspectives on their experience receiving
treatment for a chronic illness in the correctional health system to better
understand the role pharmacists may play in their care. Through the four
questions, information was successfully obtained about inmates’ perception of
medication adherence and medication management for their respective illness.
Most of the study population self-reported adherence to their medication regimen
(17/23, 73.9%) and the majority interviewed were located in halfway houses
(16/23, 69.6%). No clear difference was seen in the reported adherence between
the physical and mental illness groups.
Responses to all questions from halfway house and prison participants were
consistent in nature, likely because halfway house residents experienced the same
care processes in the recent past. When medication changes were reported, they
almost always occurred with the goal of reducing side effects to make treatment
bearable for the patient. As well, when changes were warranted, there was no
dissatisfaction with the therapeutic alternative expressed among interviewed
inmates.
The 16 total themes could be more broadly grouped into those relating to
adherence, non-adherence, or management (Appendix- Table 3). The theme
Patient Education was the only theme identified across multiple questions;
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appearing in Q1, Q3, and Q4. Education most commonly comes in the form of
providing information about the specific medication, the patient's disease,
medication or intervention adherence, and chronic disease to support therapy
effectiveness28. Whether it be doctors, nurses, or other health care workers
providing support to inmates- knowledge is passed from provider to patient and
ultimately translates into adherence. This is important in that it provides evidence
of the role clinicians play in supporting medication adherence as well as
facilitating the management of an inmate-patients’ medication regimen.
Patient education can be a tool for combating identified recurring causes of
non-adherence such as Lack of Need, Lack of Faith, Personal Beliefs, and
Unmatched Expectations. In any of these cases, the provider becomes
instrumental in communicating the purpose of therapy to the patient while also
dispelling any misinformation. The variety of ways to apply patient education
stresses how provider intervention is essential to medication management and
adherence of the inmate-patient.
Medication requests, in response to side effects or simply patient desire, and
subsequent medication therapy management warrant additional discussion due to
the impact on inmate-patient care. To start, changes to medication regimens in
correctional health facilities mirror that of the free world. For example, a
physician may increase a dose if a medication’s effects are not apparent, decrease
the dose, switch to a therapeutic alternative, or the patient may request a change if
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they are not experiencing the outcomes they desire. At times, inmate-patients
would request a medication to help with sleep or anxiety, but often these
medications are highly controlled or off limits in the prison and could not be
prescribed. The majority of participants reported at least one self-requested
alteration to their medication regimen, most commonly in response to side effects,
which was almost always accommodated by the clinician. Antipsychotics were
the medication class for which participants most frequently requested alterations,
with justifications supported primarily by Q3. Side effects such as weight gain,
extra-pyramidal symptoms (EPS), and dizziness contributed frequently as barriers
to adherence. With a metabolic role, the weight gain, and potential for
irreversibility, the EPS, close therapeutic monitoring is required by providers.
Higher incidence of type 2 diabetes mellitus, cardiovascular disease, and life-long
tardive dyskinesia (a subset of EPS) coinciding with antipsychotic therapy
warrants transition to therapeutic alternatives to prevent patient morbidity29,30.
Thus, it is expected that patients requiring antipsychotics will receive a greater
degree of medication management during their time in prison. Aside from the
antipsychotic medications, participants expressed minimal complaints about
current side effects. Overall, inmate-patients on antipsychotic therapy in prison
represent a high-risk population that require specialized attention from
correctional health care providers.
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Of additional importance was the expression of Lack of Provider Access
among interviewed inmate-patients. For those located in prison, a medication
change could be obtained through writing a sick note or reporting their symptoms
to a member of the health staff. This process could take substantial time, often
two to four weeks, for the inmate's request to be triaged appropriately and for a
session with a physician to become available. For medications requiring frequent
side effect and efficacy monitoring, such as the antipsychotics, delays in seeing a
care provider could negatively impact care. Thus, in both the prison and extended
supervision populations, this theme was ultimately viewed as a barrier to
medication adherence and routine care.
Previously, for an inmate-patient in the halfway house, changing their regimen
proved difficult as it required they receive all medical care back at the prison they
originally came from. New regulations brought on by the Affordable Care Act
(ACA) work to reduce this barrier to care by allowing halfway house residents to
purchase private insurance or qualify for Medicaid and Medicare on release31,32.
Inmate-patients can now utilize this insurance during their time in extended
surveillance to improve their access to care in the community. Allowing inmates
to access community-based health services directly while in the halfway house
helps to establish the halfway house residents’ care team at an early stage,
allowing them to adapt to their new settings, and potentially reduce provider
burden in the correctional health care system. Involving insurance and other
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regulatory bodies at an earlier stage in transition, may effectively address the
expressed barrier of Limited Provider Access. Putting inmate-patients in a
position to easily and regularly make use of their care team, with access to the
educational support of their clinicians, will likely promote optimal adherence and
allow for realization of the greatest benefits from therapy.
Previous research into inmate-patient perspectives on barriers or facilitators of
adherence primarily focuses on the experiences of specific disease-states in the
correctional setting. The majority of adherence research relates to inmate-patients
with HIV/AIDS or psychiatric illnesses, with data lacking for chronic conditions
such as hypertension and asthma. Interviews conducted with incarcerated women
suffering from HIV identified factors such as increased knowledge of their
disease, improving CD4 levels, privacy associated with “keep on person”
medications, and the routine of prison life as factors enhancing medication
adherence among others. Conversely, this same study found the stigma of
receiving antiretroviral therapy for HIV and participating in the medication line as
barriers to adherence33.
Another study, analyzing factors associated with former inmate HIV patients'
use of health care on release, found that major factors related to interpersonal
relationships, professional relationships, coping strategies and resources, and
individual attitudes affected health care utilization34. This study is similar to the
current findings in the sense that "professional relationships" and "coping
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strategies and resources" coincide with the receipt of Patient Education from
correctional health care providers. For those receiving psychotropic medications,
a review by Shelton et al. found that factors influencing medication adherence
could be generally grouped into the following categories: prisoner demographic
characteristics, prior use of psychotropic medication, prisoner insight into mental
health treatment needs, prison environment, and medication side effects35. In a
randomized controlled trial among female inmate-patients with bipolar disorder,
authors found that inmate-patients skipping the greatest number of doses had the
lowest levels of baseline adherence and most severe symptoms36. Conversely,
they found that as adherence increases over time, each inmate reported symptoms
decreased, considered a sign of therapy effectiveness. In this same study, mood
stabilizers, such as lithium, were the most commonly skipped medication
followed by antipsychotics36. In the current study, findings provide justification
for skipping these medications as participants complained of Cognitive Side
Effects, Therapy-limiting Side Effects, and Physical Side Effects when referring
to lithium and antipsychotics. Since mood-stabilizers and antipsychotics are the
main form of treatment for a variety of mood disorders, such as bipolar disorder
and schizophrenia, addressing side effects and other associated barriers to
adherence becomes increasingly important for the achievement of therapeutic
goals. This study builds upon the themes identified previously in the literature and
presents a diversity of other factors affecting inmate adherence.
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Pharmacist Role
A pharmacist has the capacity to serve in many roles due to their broad
knowledge base and in-depth familiarity with medication use and distribution.
Previous studies have proven the pharmacist's ability to directly monitor
therapeutic levels, prevent and address side effects, provide education, and reduce
costs in a variety of settings while striving to achieve optimal therapy goals14,28,37–
41

. In general, pharmacists are currently employed by community pharmacies,

hospitals, ambulatory care clinics, and a variety of outpatient settings.
Pharmacists are also found in the correctional health system and have
responsibilities ranging from verifying medications for administration to
collaborative drug therapy agreements (CDTA) where they carry out
comprehensive medication management for specific populations. Commonly
managed disease-states include HIV, hepatitis, diabetes, and patients receiving
anticoagulation42–44.
Opportunities for specialization in correctional health care exist for pharmacy
school graduates in the form of a pharmacy residency. Examples of programs
currently offered in correctional health care include UConn Health’s Correctional
Managed Health Care (CMHC) residency and University of Texas Medical
Branch’s (UTMB) managed care pharmacy45,46. At the Federal level, the Bureau
of Prisons (BOP) residency exists and offers training in mental health, ambulatory
care, and diabetes management among other specialties43,47. With the
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aforementioned opportunities in mind, the recent ASHP guidelines for
pharmacists in correctional settings further cement the clinical benefits offered by
the pharmacist22. The results of this study offer insight into how the pharmacist
can further serve the correctional population while continuing to advance their
role as a provider by delivering safe and efficacious care. Applications of the
pharmacist’s skillset have been developed to achieve this end and are suggested in
the following paragraphs.
The two main functional areas identified for pharmacist intervention are the
outpatient and inpatient segments of the care continuum, with the most substantial
improvement possible in the inpatient setting. From an inpatient perspective, care
delivered specifically within the prison medical department, it is clear that
populations with chronic illnesses require continual medication management and
the current availability of providers is limited. As previously mentioned, the side
effect profile of antipsychotics requires close monitoring and frequently
necessitates therapeutic alterations. Pharmacists are well equipped to address this
medication monitoring need after receiving the Board Certified Psychiatric
Pharmacist (BCPP) credential that exists through the Board of Pharmacy
Specialties (BPS)48. For this certification, pharmacists are required to have
practiced for from two to four years, based on residency experience, with a
percentage of their time devoted to psychiatric pharmacy activities and must
objectively demonstrate their knowledge by sitting for a board examination48.
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CDTA’s for the psychiatric population exist in certain care settings, and should be
further implemented to allow pharmacists to practice at the top of their license.
The BPS also offers the Board Certified Pharmacotherapy Specialist (BCPS)
credential49. With this, the pharmacist has demonstrated an in-depth knowledge of
medications and can effectively provide comprehensive medication therapy
management (MTM) for many different disease-states49.
Under the care of a BCPS or BCPP certified pharmacist, each patient’s
medication regimen could be optimized to reduce drug interactions, limit side
effects, and titrated to achieve therapeutic goals. Employing pharmacists with
either the BCPP or BCPS credential works to combat the provider shortage in
prisons, resolving issues specific to this psychiatric population and other disease
state, ultimately allowing the primary care physicians to focus their limited time
on other aspects of patient care. In this way, another care provider would be made
available to the correctional health system, impacting medication adherence
through optimum medication management. As well, the pharmacist can help
address inmate-patients that may be resistant to therapy through motivational
interviewing. Combined with pharmacist's empathy, applying motivational
interviewing to the incarcerated population could foster change that could
improve adherence and extend to other aspects of the patient's life.
From an outpatient standpoint, the pharmacist has the potential to increase
their functionality to released inmates by working within the existing health
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infrastructure. For released inmates, there is often misinformation about how to
reengage in health care on return to the community. Without this information, the
inmate is at risk of failing to reestablish their care team which could contribute to
non-adherence. Other factors affecting adherence for any patient in the
community include costly medications, lack of care coordination, and personal
factors such as patient health literacy and support networks4. Since inmates
become responsible for all health care on release, it can be inferred than an extra
form of support would help them with this transition. As stated earlier, the
abundance of community pharmacies in the United States gives inmates an easy
source of health information on release from prison. Pharmacists serve a broad
population of patients in the community pharmacy, but may not be privy to the
experience of those released from prison. Without knowledge of the transitions of
care that occur between prison and the community, or extended surveillance and
community, the pharmacist cannot serve inmate-patient’s post-incarceration to the
best of their ability. Community support programs exist to help patients navigate
during the high-risk transitionary period, but no relationship between these
programs and community pharmacies currently exists. A synergistic solution
would be for community pharmacies to establish contact with community health
programs to facilitate post-incarcerated patients’ integration into the health
system. As a regular member of interdisciplinary care teams, pharmacists have
significant experience with interprofessional communication and exposure to a
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diversity of care settings; allowing for effective communication to and from
community health programs.
Additionally, if the pharmacist were to have greater knowledge of the
patient’s needs post-incarceration, they could direct patients to appropriate health
services or, with knowledge of their transitional health coverage, suggest cheaper
payment methods. An example of the former would consist of a post-incarcerated
patient coming to the pharmacy without an established primary care physician,
requesting more information. The latter could occur when the patient’s insurance
coverage has not been instated on release from prison and needs medication. In
this case, the pharmacist can utilize a prescription discount card, which are
common in the community pharmacy, or offer recommendations for low cost
over-the-counter (OTC) medications to help the patient save money. Through the
community pharmacy, the pharmacist would be addressing transitional adherence,
a critical step in the inmate-patient’s care process, in addition to the normal dayto-day needs of released inmates.
To better prepare pharmacists, there should be a coordinated effort between
the prison facility, government at local and state levels, community health
programs, and community pharmacies as a whole. A potential solution would be
the implementation of a certification program, recurring academic seminar, or
Continuing Education credit that provides pharmacists with knowledge they need
to manage this vulnerable population. While the pharmacist already services this
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population in several ways, pharmacists have the potential to do much more from
the inpatient and outpatient standpoints. Whether providing education and
guidance to promote adherence in the community pharmacy, or directly managing
medications in the correctional health setting, there are strides to be made for
pharmacists in the realm of correctional health.

Limitations
While every effort was made to ensure the rigor of this study, several limitations
were present that prevent complete realization of the true scope of inmate-patient
perspectives on health care. The most significant limitation was the inability to
obtain inmate-patients' Medication Administration Records (MAR) due to
scheduling, travel, and administrative barriers. Using the MAR would have
provided an objective source for evaluating the patient's overall adherence and
could have served as a cross-reference to their self-reported answer. Using
patients' self-reported adherence served as a less accurate marker but was
ultimately the only available resource. While there is no perfect measure of
adherence, the standard used is often proportion of days covered (PDC). For
instance, the Pharmacy Quality Alliance (PQA) uses PDC as their standard
measure of adherence when developing medication-use measures for medication
safety and adherence26,27.The PDC is calculated by the total days of medication
supply during a time interval divided by the total length of time in the interval
period; yielding the percentage of days with medication available50 This
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calculation is often made through evaluation of pharmacy claims data, by
comparing the fill dates of the patient's medication27. A patient is often considered
adherent when their PDC is 80% or more for a given period of time, and nonadherent below this threshold51. To go along with the missing MAR data, this
study did not use other objective forms of data collection such as surveys, scales,
or questionnaires. Employing these methods would have allowed for greater data
standardization, comparison among participants, and potentially the use of
statistical analysis.
Second, the open-ended questions could be deemed ambiguous and open to
interpretation by each interviewee. Additional probing may have elicited different
responses from participants that may have varied between different interviews.
Recruiting also presented as a major limitation for this study. By passively
posting fliers in the prisons and halfway houses, inmates could have easily
overlooked or forgotten to self-enroll in the study. The final cohort of 23
participants yielded interesting themes, but further evidence could have been
generated from a larger and more diverse group of participants. Among the
patient population, there was an imbalance between adherent and non-adherent
with the majority of participants reporting adherent. This imbalance may be
explained by the recruiting method, as it could be inferred that the non-adherent
population did not care enough to participate in the study since they already do
not actively participate in their treatment. A more active approach, such as
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planned informational sessions regarding the study and face-to-face enrollment,
may have yielded a more balanced study population. As well, the interviewed
population did not include female inmate-patients, so the study is restricted to
purely the male's perspective of the correctional health setting. In terms of
stratification of the interviewed population, the analysis primarily focused on the
main diagnosis of the patient and was not segregated based on the type of
medication. Again, the absence of MAR data prevented further stratification of
the study participants.

Future Research
As stated, inmate medication adherence is understudied and is primarily focused
in select disease-states such as HIV/AIDS and mental illnesses. However, even
these disease states, are understudied and current research does not fully capture
inmate-patient perspectives on medication adherence and experience with
medication management. Thus, additional studies in a diversity of disease states
using objective measures of adherence must be conducted to further evaluate
factors affecting adherence in the correctional health setting. This study has
identified themes surrounding inmate-patient perspectives on medication
adherence and management. Building upon this, strategies for integrating
pharmacists in the inpatient and outpatient settings may provide a means of
addressing deficits in adherence at key junctures in the correctional care process

40

while efficaciously employing pharmacists' unique skillset for optimum
medication therapy management.
While the proposed roles for the pharmacist make theoretical sense, additional
studies are necessary to gauge the value of direct pharmacist intervention on the
adherence and subsequent health outcomes of inmate-patients. A potential study
would be to compare inmate-patients supplied with intensive pharmacist
medication management in the inpatient setting to a cohort with the facility’s
current standard of care. Assessing measures such as adherence, well-being, cost
of care, and quality of life would prove a means of evaluating pharmacists' impact
in this role. In the outpatient setting, development of resources to educate
community practitioners about the path of inmate-patients on reintegration to the
community will serve as the next best step forward. Future studies should also
capture inmate-patient perspectives specifically on the pharmacist and their roles
in both the correctional setting and in the community. Utilization of the
pharmacist’s services in these settings was not captured in the present study, but
may offer additional clues in regards to how inmate-patients access care.
Additional studies are suggested to examine pharmacist involvement with the
patient, but also with other providers in the correctional health setting. The theme
Limited Provider Access demonstrated the frustration inmate-patients experienced
when trying to utilize the health service in pursuit of medication inquiries or
routine care. An expanded role for pharmacists should be explored, supported by
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data regarding current provider time burden, illuminating value added supplied by
the pharmacist. The prevalence of Patient Education throughout this study also
calls for a greater assessment of the type of education most commonly provided to
inmate-patients and the content most commonly requested. From an alternate
perspective, the quality of the patient-provider relationship can be assessed in
order to understand those essential factors that facilitate communication of
medication education. At the end of the day, the patient is first and foremost in
any health care setting. Studies to identify key factors of importance throughout
inmate-patients' experience with correctional health care will provide evidence to
better facilitate the implementation of patient-centered care in the correctional
health setting.

Conclusion
Themes identified suggest the benefit of patient education in both the inpatient
correctional health setting and outpatient on inmates’ transition to the community.
From the inpatient setting, pharmacists are well suited to perform comprehensive
medication therapy management for the psychiatric population and other chronic
illnesses. In an outpatient setting, the community pharmacist is poised to supply
medication and additional health information to inmates in transition. Interviews
conducted during this study provided valuable new details regarding inmatepatient perceptions of medication adherence and medication therapy management
as a part of their treatment regimen. Overall, the pharmacist’s adept medication
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knowledge and availability allow for in-depth medication management and
support of inmates’ medication adherence. Further incorporation of the
pharmacist into correctional health care will allow for increased patient-centered
care and will likely bring about improvements in this population’s health.
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Appendices
Table 1. Projected Parent Study Enrollment
Patient Groups
Adherent
Diabetes
Hypertension
HIV/AIDS
Schizophrenia
Bipolar
Depression
Substance Abuse

Male - 5
Male - 5
Male - 5
Male - 5
Male - 5
Male - 5
Male - 5

Female - 5
Female - 5
Female - 5
Female - 5
Female - 5
Female - 5
Female - 5

Non-adherent
Male - 5
Male - 5
Male - 5
Male - 5
Male - 5
Male - 5
Male - 5

Female - 5
Female - 5
Female - 5
Female - 5
Female - 5
Female - 5
Female - 5

Table 1 Description: The projected enrollment for the “Inmate Self Care” study
was 140 participants to ensure saturation among each of the specified groups of
interest. Adherence or non-adherence was assigned based on review of the
inmate-patients’ medication administration record (MAR) or, if MAR was
unavailable, based on the patient's self-reported response based on their overall
sense of adherence for the previous 3 months.
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Table 2. Sub- study Sample Demographics
Demographics:
Gender:
Male
Location:
Prison
Halfway House
Primary Dx:
Hypertension
Diabetes Mellitus
HIV/AIDS
Depression
Bipolar Disorder
Schizophrenia
Substance Abuse
Ethnicity:
Black
Hispanic
White/Caucasian
Other
Education:
College Degree
High
School/GED/Technical
Some High School
Other
Family Support:
Yes
No

Adherent n=17
%

Non-adherent n=6
%

Total N=23
%

17

6

23

5
12

2
4

7
16

1
2
3
4
2
2
3

0
1
0
3
1
1
0

1
3
3
7
3
3
3

8
5
2
2

1
0
3
2

9
5
5
4

3

1

4

5
7
2

5
0
0

10
7
2

13
4

3
3

16
7

Table 2 Description: The mental illness group contained primary diagnoses of
depression, bipolar disorder, schizophrenia, and substance abuse. The physical
illness group contained the diagnoses of hypertension, diabetes mellitus, and
HIV/AIDS. Adherence status was based on patient self-report based for the
previous 3 months. Halfway house or prison location was based on place when
interviewed. For Education, college degree includes bachelors or associates;
‘Other’ classification includes some college (1) or unassigned (1). For Ethnicity,
the ‘Other’ classification represents unknown (1) and mixed race (3).
Abbreviations: Dx=Diagnosis
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Figure 1. Theme Web
Momentary Disruptions
Timeliness
Lack of Need
Personal Beliefs

Tangible Benefits
Potential Risks

Q1

Q2

Acute Relief
Counseling
Loss of Faith

Patient Education

Cognitive Side Effects
Therapy-limiting Side Effects
Physical Side Effects

Q3

Q4

Unmatched Expectations
Limited Provider Access
Data Use

Figure 1 Description: The web shows the themes identified when each question
was asked. The red lines extending from each box signify the presence of the
theme Patient Education among questions 1, 3, and 4.
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Table 3. Adherence, Non-adherence, Management Theme Classifications
Adherence
Acute Relief
Counseling
Potential Risks
Patient Education
Tangible Benefits

Non-adherence
Cognitive Side Effects
Lack of Need
Lack of Provider Access
Loss of Faith
Momentary Disruptions
Personal Beliefs
Physical Side Effects
Therapy-limiting Side Effects
Timeliness
Unmatched Expectations

Management
Cognitive Side Effects
Data Use
Lack of Provider Access
Physical Side Effects
Patient Education
Therapy-limiting Side Effects
Unmatched Expectations

Table 3 Description: Thematic classification from Q1, Q2, Q3, Q4 could be
separated based on the impact they had on either adherence or medication
management. Themes were separated based on the context they were presented
from the interview participant. The adherence designation suggests the theme
promotes proper medication adherence, and non-adherence suggests the theme
detracts from proper medication adherence. Management is a compilation of
themes that are important for optimum medication therapy management.
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